Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 5/20 | 0.80 |
| ▸ | GSK3B | P49841 | 8/20 | 0.71 |
| ▸ | CDK5 | Q00535 | 6/20 | 0.71 |
| ▸ | CDK5R1 | Q15078 | 6/20 | 0.71 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.71 |
| ▸ | CLK1 | P49759 | 4/20 | 0.71 |
| ▸ | CCNB2 | O95067 | 3/20 | 0.71 |
| ▸ | CDK1 | P06493 | 3/20 | 0.71 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.71 |
| ▸ | PRKACA | P17612 | 3/20 | 0.71 |
| ▸ | PRKACG | P22612 | 3/20 | 0.71 |
| ▸ | PRKACB | P22694 | 3/20 | 0.71 |
| ▸ | CCNB3 | Q8WWL7 | 3/20 | 0.71 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.71 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.71 |
| ▸ | CSNK1E | P49674 | 2/20 | 0.71 |
| ▸ | CSNK1G2 | P78368 | 2/20 | 0.71 |
| ▸ | CSNK1G1 | Q9HCP0 | 2/20 | 0.71 |
| ▸ | NFATC1 | O95644 | 1/20 | 0.63 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28492625 | 1.00 | MAP3K14 (0.80) | MAP3K14GSK3BCDK5CDK5R1DYRK1A | |
| SCHEMBL28387230 | 0.84 | GSK3B (0.58) | MAP3K14GSK3BCDK5CDK5R1DYRK1A | |
| SCHEMBL30436968 | 0.84 | GSK3B (0.58) | MAP3K14GSK3BCDK5CDK5R1DYRK1A | |
| Meridianin D SCHEMBL23539138 | 0.83 | GSK3B (1.00) | MAP3K14GSK3BCDK5CDK5R1DYRK1A | |
| SCHEMBL29488164 | 0.83 | GSK3B (0.71) | MAP3K14GSK3BCDK5CDK5R1DYRK1A | |
| SCHEMBL28982786 | 0.83 | GSK3B (1.00) | MAP3K14GSK3BCDK5CDK5R1DYRK1A | |
| SCHEMBL23175317 | 0.83 | GSK3B (0.71) | MAP3K14GSK3BCDK5CDK5R1DYRK1A | |
| SCHEMBL30369123 | 0.83 | GSK3B (1.00) | MAP3K14GSK3BCDK5CDK5R1DYRK1A | |
| Meridianin D SCHEMBL31094009 | 0.83 | GSK3B (1.00) | MAP3K14GSK3BCDK5CDK5R1DYRK1A | |
| SCHEMBL30369693 | 0.83 | GSK3B (1.00) | MAP3K14GSK3BCDK5CDK5R1DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12350265-B2 | Pharmaceutical composition for treating acute myeloid leukemia, containing FLT3 inhibitor and chemotherapeutic agents | HANMI PHARM. CO., LTD. (KR) | 2025-07-08 | — | — | US | claimed |
| US-20220354842-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING ACUTE MYELOID LEUKEMIA, CONTAINING FLT3 INHIBITOR AND CHEMOTHERAPEUTIC AGENTS | HANMI PHARM. CO., LTD. (KR) | 2022-11-10 | — | — | US | claimed |
| US-20260092051-A1 | PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING CANCERS INCLUDING THE SAME | HANMI PHARMACEUTICAL CO LTD (KR) | 2026-04-02 | — | — | US | disclosed |
| US-12433867-B2 | Pharmaceutical composition comprising FLT3 inhibitor and hypomethylating agent for treating acute myeloid leukemia | HANMI PHARM. CO., LTD. (KR) | 2025-10-07 | — | — | US | disclosed |
| US-12350265-B2 | Pharmaceutical composition for treating acute myeloid leukemia, containing FLT3 inhibitor and chemotherapeutic agents | HANMI PHARM. CO., LTD. (KR) | 2025-07-08 | — | — | US | disclosed |
| US-12325698-B2 | Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same | HANMI PHARM. CO., LTD. (KR) | 2025-06-10 | — | — | US | disclosed |
| CN-115925686-B | MERIDIANIN derivatives, lewis acid-promoted coupling synthesis method and application thereof | 贵州医科大学 | 2024-07-30 | — | — | CN | disclosed |
| CN-116693506-A | Pyrimidine compound and pharmaceutical composition for preventing or treating cancer comprising the same | 韩美药品株式会社 | 2023-09-05 | — | — | CN | disclosed |
| US-20230002358-A1 | PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING CANCERS INCLUDING THE SAME | HANMI PHARM. CO., LTD. (KR) | 2023-01-05 | — | — | US | disclosed |
| US-20220354842-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING ACUTE MYELOID LEUKEMIA, CONTAINING FLT3 INHIBITOR AND CHEMOTHERAPEUTIC AGENTS | HANMI PHARM. CO., LTD. (KR) | 2022-11-10 | — | — | US | disclosed |
| US-20220110913-A1 | PHARMACEUTICAL COMPOSITION COMPRISING FLT3 INHIBITOR AND HYPOMETHYLATING AGENT FOR TREATING ACUTE MYELOID LEUKEMIA | HANMI PHARM. CO., LTD (KR) | 2022-04-14 | — | — | US | disclosed |
| US-11292786-B2 | Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same | HANMI PHARM. CO., LTD. (KR) | 2022-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002358-A1 | PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING CANCERS INCLUDING THE SAME | DPYD, TYMS, TYMP | MAP3K14 2292/4885GSK3B 3481/4885CDK5 438/4885 |
| US-20220110913-A1 | PHARMACEUTICAL COMPOSITION COMPRISING FLT3 INHIBITOR AND HYPOMETHYLATING AGENT FOR TREATING ACUTE MYELOID LEUKEMIA | FLT3, MCL1, HGFAC | MAP3K14 264/4885GSK3B 501/4885CDK5 1445/4885 |
| US-12325698-B2 | Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same | DPYD, TYMS, TYMP | MAP3K14 2292/4885GSK3B 3481/4885CDK5 438/4885 |
| US-20220354842-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING ACUTE MYELOID LEUKEMIA, CONTAINING FLT3 INHIBITOR AND CHEMOTHERAPEUTIC AGENTS | FLT3, MCL1, CSF3R | MAP3K14 338/4885GSK3B 486/4885CDK5 845/4885 |
| US-12350265-B2 | Pharmaceutical composition for treating acute myeloid leukemia, containing FLT3 inhibitor and chemotherapeutic agents | FLT3, MCL1, CSF3R | MAP3K14 338/4885GSK3B 486/4885CDK5 845/4885 |
| US-11292786-B2 | Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same | DPYD, TYMS, TYMP | MAP3K14 2292/4885GSK3B 3481/4885CDK5 438/4885 |
| US-12433867-B2 | Pharmaceutical composition comprising FLT3 inhibitor and hypomethylating agent for treating acute myeloid leukemia | FLT3, MCL1, HGFAC | MAP3K14 264/4885GSK3B 501/4885CDK5 1445/4885 |
| US-20260092051-A1 | PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING CANCERS INCLUDING THE SAME | FLT3, FLT1, ADK | MAP3K14 345/4885GSK3B 152/4885CDK5 715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.